Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa.

Some Medicare Part D plans did not cover authorized generic versions of pricey hepatitis C drugs, with rebates likely to blame, an OIG report found.

The state chose Gilead Sciences’ new generics business, Asegua Therapeutics, to team up on its “Netflix” subscription model for unlimited access to an authorized Epclusa copycat.

Gilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls for lower drug prices because of spiralling healthcare costs. The California pharma’s ...

The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epclusa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for ...